Early Endovascular Repair Versus Surveillance for Women With Small Abdominal Aortic Aneurysm

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age50+
SponsorImperial College London

About this trial

Elective Abdominal Aortic Aneurysm (AAA) repair is offered when the risk of rupture exceeds the risk of surgery. Women (versus men) have a four-fold higher risk of AAA rupture but almost double the operative mortality. It is unknown whether the current 5.5cm diameter AAA repair threshold, derived from randomised trials including only 4% women, is applicable to women.

Therefore, should women have their aneurysms repaired electively at smaller diameters than men to improve their AAA-related survival and quality of life? WARRIORS is an international randomised controlled trial of early elective endovascular repair versus routine surveillance in women (n=1112) with small asymptomatic AAA (4-5.4cm diameter), nested within a registry of non-participants. The surveillance group will be offered repair for rupture or upon reaching the 5.5cm threshold. Randomisation will be 1:1 stratified by country, age, and aneurysm diameter. The trial is powered for aneurysm-related mortality or rupture at 5 years. Quality-Adjusted-Life-Years is a major secondary outcome. Other outcomes include: operative mortality and complications, anxiety, major cardiovascular adverse events, and cost-effectiveness. Quality-of-life and anxiety questionnaires and "standard-of-care" using routine data will be collected.

The trial aims to progress health equity through provision of evidence for sex-specific clinical guidelines for AAA repair.

Eligibility criteria

Qualifiers

female sex

age ≥50 years

infra-renal abdominal aortic aneurysm with a maximum infrarenal aortic anterior-posterior diameter 4.0-5.4 cm, aneurysm, measured on ultrasonography or the centreline orthogonal diameter on Computed Tomography (CT) scan when this is the discovery imaging mode,

Local assessment that arterial morphology is suitable for EVAR within manufacturer's IFU for any licensed infrarenal endograft, including those with concomitant common iliac aneurysm(s), provided the device is landed in the iliac arteries, without coverage of patent internal iliac arteries.

Disqualifiers

Male sex

aneurysm of the infrarenal aorta of <4.0 or >5.4cm

infrarenal aneurysm not meeting IFU for any specific licensed endograft for standard EVAR

inability to give informed consent

Trial design

Treatments tested in this trial

  • EVAR

Treatment groups

1,112 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Imperial College London

Lead sponsor

University College, London

Collaborator

University of Leicester

Collaborator

St Georges University Hospital

Collaborator

University of Southern Denmark

Collaborator